ENTO Key Statistics, Chart & Performance
The current stock price of ENTO is 2.99 USD. In the past month the price decreased by -32.51%. In the past year, price increased by 110.49%.
ENTO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.29 | 388.96B | ||
| AMGN | AMGEN INC | 14.91 | 175.60B | ||
| GILD | GILEAD SCIENCES INC | 14.79 | 150.25B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.72 | 117.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.7 | 83.72B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 780.96 | 52.62B | ||
| INSM | INSMED INC | N/A | 37.53B | ||
| NTRA | NATERA INC | N/A | 32.34B | ||
| BIIB | BIOGEN INC | 11.21 | 27.52B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.31 | 20.81B | ||
| INCY | INCYTE CORP | 16.65 | 20.98B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.94B |
Related stock screener links
About ENTO
Company Profile
Entero Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of targeted, non-systemic therapies for the treatment of patients with gastrointestinal diseases. The company is headquartered in Boca Raton, Florida and currently employs 2 full-time employees. The company went IPO on 2016-10-11. The firm is engaged in the research and development of targeted, non-systemic therapies for the treatment of patients with gastrointestinal (GI) diseases. The firm is focused on developing the biologic Adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis (CF) and chronic pancreatitis (CP) patients with exocrine pancreatic insufficiency (EPI). Adrulipase is the active pharmaceutical ingredient (API) derived from Yarrowia lipolytica, an aerobic yeast naturally found in various foods such as cheese and olive oil that is widely used as a biocatalyst in several industrial processes. The firm is developing Adrulipase for two principal therapeutic indications: children and adults affected by CF, and adult patients with CP.
Company Info
ENTERO THERAPEUTICS INC
777 Yamato Road, Suite 502
Boca Raton FLORIDA US
Employees: 2
Phone: 15615897020
ENTERO THERAPEUTICS INC / ENTO FAQ
What does ENTO do?
Entero Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of targeted, non-systemic therapies for the treatment of patients with gastrointestinal diseases. The company is headquartered in Boca Raton, Florida and currently employs 2 full-time employees. The company went IPO on 2016-10-11. The firm is engaged in the research and development of targeted, non-systemic therapies for the treatment of patients with gastrointestinal (GI) diseases. The firm is focused on developing the biologic Adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis (CF) and chronic pancreatitis (CP) patients with exocrine pancreatic insufficiency (EPI). Adrulipase is the active pharmaceutical ingredient (API) derived from Yarrowia lipolytica, an aerobic yeast naturally found in various foods such as cheese and olive oil that is widely used as a biocatalyst in several industrial processes. The firm is developing Adrulipase for two principal therapeutic indications: children and adults affected by CF, and adult patients with CP.
What is the stock price of ENTERO THERAPEUTICS INC today?
The current stock price of ENTO is 2.99 USD. The price increased by 5.28% in the last trading session.
Does ENTO stock pay dividends?
ENTO does not pay a dividend.
How is the ChartMill rating for ENTERO THERAPEUTICS INC?
ENTO has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Which stock exchange lists ENTO stock?
ENTO stock is listed on the Nasdaq exchange.
ENTO Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to ENTO. When comparing the yearly performance of all stocks, ENTO is one of the better performing stocks in the market, outperforming 95.32% of all stocks.
ENTO Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ENTO. Both the profitability and financial health of ENTO have multiple concerns.
ENTO Financial Highlights
Over the last trailing twelve months ENTO reported a non-GAAP Earnings per Share(EPS) of -11.09. The EPS increased by 76.71% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -20.48% | ||
| ROE | -31.45% | ||
| Debt/Equity | 0.01 |